Popper and Company

What Popper and Company does

Popper and Company is a privately held boutique consulting firm founded in 2003 by Caroline Popper, MD and Kenneth G. Walz, headquartered in Baltimore, Maryland. The firm provides M&A advisory and specialty consulting services to life sciences companies and institutional/strategic investors, with a core focus on diagnostics, medical devices, and biotechnology. The firm's service portfolio is organized around two pillars: Strategy Consulting (encompassing proprietary methodologies including 'Inside Out Diagnostic,' 'Blueprint to Launch,' and 'Outside In Innovation') and Transaction Advisory (target identification and selection, due diligence, and transaction process management). These services are unified by the firm's proprietary 'Smarter Healthcare' intellectual framework, which challenges the traditional Iron Triangle of Healthcare model and positions innovation at the intersection of technology, clinical practice, and market shifts.

The firm's commercial model is professional services, with revenue generated through project-based and likely retainer engagements with enterprise clients in life sciences. Customer segments include early-stage diagnostics and medical device startups, established life sciences enterprises (Roche, Danaher, multinational pharmaceutical and diagnostic companies), institutional and strategic investors, and academic health science centers. The firm operates a sales-led, relationship-driven go-to-market motion with no public pricing tiers and bespoke engagement structures. Geographic reach spans North America, Europe (UK, Germany, Switzerland), Australia, and Asia (China), supported by a senior advisor network with international operating experience.

Popper's team comprises physician entrepreneurs, PhD scientists, engineers, and clinicians with prior leadership roles at Becton Dickinson, bioMerieux, MDS, Novartis, Covance, Janssen, the FDA, and other major life sciences organizations. The firm has demonstrated measurable client outcomes including FDA 510(k) de novo approvals, CE marking achievements, successful joint venture formations, and portfolio expansions in oncology and precision medicine. Popper operates as a founder-managed private firm with no disclosed institutional investors, parent company, or external equity partners, and does not publicly disclose revenue figures.

Name

Popper and Company

Legal name

Popper and Company

Website

https://popperandco.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Popper and Company is a privately held boutique life sciences consulting and M&A advisory firm founded in 2003, serving diagnostics, medical device, and biotech companies plus institutional investors with strategy consulting and transaction advisory services.

Ownership category

akta.pro rank

Headquarters

HQ city

Sarasota

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Strategy Consulting: Popper and Company generates revenue by providing strategy consulting services to life science companies, including product conception, commercialization strategy, and regulatory/go-to-market advisory. Fees are likely project-based or retainer arrangements typical of boutique consulting firms.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Popper and Company is a boutique life sciences consulting firm that provides strategy consulting and transaction advisory services to diagnostics, medical device, biotech, and pharmaceutical companies, as well as to institutional and strategic investors. Its core offerings center on the proprietary Smarter Healthcare framework and include commercial strategy development, regulatory and market entry advisory, and full M&A and partnership transaction support from target identification through deal closing.

Product overview

Popper and Company is a life sciences consulting firm offering a unified portfolio of advisory services centered on its Smarter Healthcare framework. The core offerings comprise Strategy Consulting (featuring Inside Out Diagnostic, Blueprint to Launch, and Outside In Innovation methodologies) and Transaction Advisory (encompassing Target Identification & Selection, Due Diligence, and Transaction Process Management). These services work together to provide clients with comprehensive guidance from internal assessment through market entry, helping companies develop and commercialize new technologies in diagnostics, medical devices, and life sciences.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategy Consulting Comprehensive consulting service for life sciences companies spanning product conception, commercialization strategy, regulatory and market entry advisory, and innovation strategy. Designed for diagnostics, medical device, biotech, and pharmaceutical companies at all stages.
• Transaction Advisory Advisory services for mergers, acquisitions, and strategic partnerships in the life sciences sector, including target identification, due diligence, and full transaction process management. Serves life sciences companies and institutional/strategic investors.

Quantifiable outcome

• Popper helped LBT Innovations achieve FDA 510(k) de novo approval in 2016 for AI imaging and software used as a medical device.
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LBT InnovationscoreStrategic or Co-development PartnerLBT Innovations engaged Popper and Company to develop and implement a regulatory strategy for their AI imaging technology. Popper provided project management, US study support, protocol development, clinical trial management, and FDA submission preparation, leading to successful 510(k) de novo FDA approval in 2016. The engagement demonstrates a deep consulting-advisory partnership in the medical device AI space.
• Premier Academic Health Science CentercoreStrategic or Co-development PartnerPopper helped a premier academic health science center develop and implement a risk-reduction and growth strategy, leading to a joint venture with a global clinical diagnostics and laboratory testing service provider. Popper was subsequently engaged to represent the client on the JV Board for ongoing strategic input.
• Medical Design Excellence Awards (MDEA)minorOthersDr. Stephanie Kreml served as a juror for the Medical Design Excellence Awards, a premier industry awards program for medical technology. This represents an industry participation and recognition role, not a commercial partnership.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Health Advances: Health Advances is a pure-play life sciences strategy consulting firm serving medical device, diagnostics, and biotech clients on commercial strategy and transaction advisory. It is closely comparable to Popper on target customer (early-to-commercial life sciences companies) and offering mix (strategy and transaction support).
• ClearView Healthcare Partners: ClearView is a boutique life sciences consultancy focused on pharmaceuticals, biotech, and medical devices, providing strategic advisory, commercial diligence, and M&A support. Like Popper, it specializes in healthcare-only engagements with an entrepreneur-led senior team and serves both corporate and investor clients.
• Back Bay Life Science Advisors: Back Bay is a boutique life sciences-focused advisory firm providing strategy consulting and transaction advisory (M&A, licensing, financing) to growth-stage life sciences companies and investors. Directly comparable service mix, customer profile, and engagement style to Popper and Company.
• DeciBio: DeciBio is a strategy consulting and market intelligence firm focused exclusively on genomics, diagnostics, and precision medicine. Overlap with Popper is strongest in diagnostics strategy and commercialization, though DeciBio leans more heavily on data products and market research offerings.
• Putnam Associates: Putnam Associates is a life sciences strategy consulting firm serving pharmaceutical, biotech, and medical device clients on commercial strategy, market access, and transaction support. Comparable boutique scale, life-sciences focus, and growth-stage company clientele to Popper.
• Triangle Insights Group: Triangle Insights Group is a boutique strategy consulting firm serving pharma, biotech, and medical device clients on commercial strategy and asset/diligence engagements. Direct peer in terms of customer base and project-based strategic advisory model.

Broad incumbents

• Charles River Associates (CRA): CRA is a global consulting firm with a Life Sciences practice providing economics, litigation, and management consulting services to pharma, biotech, and medical device companies. Overlaps with Popper on healthcare strategy and transaction advisory but operates at much larger scale with adjacent service lines.
• L.E.K. Consulting: L.E.K. is a global management consulting firm with a deep Healthcare and Life Sciences practice covering biopharma, medtech, and diagnostics strategy and M&A advisory. Comparable in customer and service overlap but operates at meaningfully greater scale than Popper.
• ZS Associates: ZS is a global consulting and analytics firm with a substantial healthcare and life sciences practice advising pharma, biotech, and medical technology companies on strategy, commercialization, and analytics. Touches the same buyer base as Popper but with broader capabilities and significantly greater scale.
• Simon-Kucher & Partners: Simon-Kucher is a global consulting firm with a Life Sciences and Healthcare practice focused on pricing, market access, and commercial strategy for pharma, biotech, and medical device clients. Partial overlap with Popper on commercialization strategy and pricing engagements for diagnostics/medtech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/popperandco
• Facebookfacebook.com/100003469667496
• LinkedInlinkedin.com/company/popper-and-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Popper and Company